Client News

Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer

Amsterdam, The Netherlands, August 30, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that Robbert van Heekeren is … Continue reading “Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer”

By Optimum

Apitope Announces Publication of Data in International Peer-Reviewed Journal Neurology on Novel Multiple Sclerosis Therapy

HASSELT, Belgium, and CHEPSTOW, UK, 19 March 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced publication of data on it multiple … Continue reading “Apitope Announces Publication of Data in International Peer-Reviewed Journal Neurology on Novel Multiple Sclerosis Therapy”

By Optimum

Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform

Hamburg, Germany; Paris, France, 08 March 2018 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research … Continue reading “Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform”

By Optimum

Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec

HASSELT, Belgium, and CHEPSTOW, UK, 7th March 2018 Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced the appointment of William Jenkins, M.D., … Continue reading “Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH